Caring Cross and the Global Gene Therapy Initiative Deliver Presentations at the "Advanced Therapy for Sickle Cell Disease in Africa" Meeting at Muhimbili University of Health and Allied Sciences
Retrieved on:
Tuesday, February 8, 2022
Thalassemia, Global Genes, SCD, Cell, Muhimbili University of Health and Allied Sciences, Ministry of Education (Malaysia), Aga Khan Hospital, Dar es Salaam, Gene, Joint Clinical Research Centre, HIV, Sickle cell disease, World, Bill & Melinda Gates Foundation, MUHAS, Program, Patient, JCRC, Method, Fred Hutchinson Cancer Research Center, Physician, Association, Dropull, World Health Organization, Haematopoietic system, Associate, Pharmaceutical industry, Medical device
"Caring Cross ishonored to participate in this important meeting and support the mission to accelerate the introduction of gene therapies for Sickle Cell Disease to Africa."
Key Points:
- "Caring Cross ishonored to participate in this important meeting and support the mission to accelerate the introduction of gene therapies for Sickle Cell Disease to Africa."
- Dr. Adair commented: "The Global Gene Therapy Initiative is pleased to participate in this important meeting and support the advancement of curative interventions for Sickle Cell Disease.
- Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy.
- A stem cell gene therapy for Sickle Cell Disease and Beta-Thalassemia is also in development.